News

HDAC Inhibition Improves Hypertension, Hyperglycemia in Rodent Study

Histone deacetylase inhibition (HDACi) improves hypertension and hyperglycemia in a rat model of Cushing’s syndrome (CS) by reducing activity of the glucocorticoid receptor, a new study shows. The study, “Histone Deacetylase Inhibition Ameliorates Hypertension and Hyperglycemia in a model of Cushing’s Syndrome,” was published in the…

Penn’s Fluorescent Dye Used During Surgery Identifies Pituitary Adenomas, a Cause of Cushing’s

Researchers at the Perelman School of Medicine at the University of Pennsylvania have successfully used a fluorescent dye to identify pituitary adenoma tissue during brain surgery. The study, “Folate receptor overexpression can be visualized in real time during pituitary adenoma endoscopic transsphenoidal surgery with near-infrared imaging,” was…

Fluorescent Pigment Builds Up in Cortisol-producing Tumors Associated with Cushing Syndrome, Study Reports

Fluorescent pigments accumulate in the non-cancerous adrenal gland tumors associated with Cushing syndrome, whether or not a person has a mutation associated with the disease, a study indicates. The build-up could be used a biomarker of Cushing disease some day, the researchers said. Scientists call the pigments lipofuscin granules. Granule accumulations…

NIH Awards Crinetics $2.4 Million to Develop Congenital Hyperinsulinemia, Cushing’s Therapies

Crinetics Pharmaceuticals has received two grants from the National Institutes of Health’s (NIH) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to develop nonpeptide, oral somatostatin agonists for congenital hyperinsulinemia and new therapies for Cushing’s disease. The two Small Business Innovation Research (SBIR) grants, totaling $2.4…